Financial Performance - The company's operating revenue for 2022 was ¥4,298,513,062.14, representing a year-on-year increase of 9.22% from ¥3,935,664,219.52 in 2021[13]. - The net profit attributable to shareholders for 2022 was ¥900,926,029.55, which is a 12.93% increase compared to ¥797,777,327.57 in 2021[13]. - The basic earnings per share for 2022 was ¥0.89, up 12.66% from ¥0.79 in 2021[13]. - The total assets at the end of 2022 amounted to ¥6,481,745,574.76, reflecting a 13.77% increase from ¥5,697,186,706.05 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥5,622,248,624.37, which is a 14.26% increase from ¥4,920,688,031.43 at the end of 2021[13]. - In Q4 2022, the operating revenue reached ¥1,178,387,350.86, with a net profit attributable to shareholders of ¥159,051,214.46[16]. - The company reported a cash flow from operating activities of ¥861,023,149.69 for the year 2022, which is a 22.81% increase from ¥701,117,596.67 in 2021[13]. - The company recognized government subsidies amounting to ¥46,912,734.05 in 2022, compared to ¥32,743,590.42 in 2021[17]. - The weighted average return on equity for 2022 was 17.20%, slightly down from 17.69% in 2021[13]. - The company reported a total of ¥28,166,708.35 in non-recurring gains and losses for 2022[17]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares to all shareholders, based on a total of 1,007,588,092 shares[2]. - The proposed cash dividend for 2022 is ¥2.00 per 10 shares, totaling ¥201,517,618.40, with no stock dividends or capital reserve transfers[133]. - The cumulative cash dividend amount from 2019 to 2021 was approximately ¥604.19 million, accounting for 82.77% of the average annual net profit during the same period[153]. - After the dividend distribution, the retained undistributed profit will be ¥3,776,835,195.20, to be carried forward for future distribution[133]. Market and Industry Trends - The pharmaceutical industry in China is experiencing significant growth, with healthcare expenditure as a percentage of GDP reaching 4.83% in 2022, indicating a rising demand for medical services[21]. - Chronic disease prevalence in China has reached 23%, with chronic diseases accounting for 86% of total deaths, leading to increased long-term medication and healthcare costs[21]. - The central nervous system (CNS) drug market in China is still in its early stages, with only 3% of the global CNS drug consumption, compared to 49% in the US and 26% in Europe[23]. - The aging population and rising health awareness among the public are expected to drive further growth in the pharmaceutical sector, presenting significant opportunities for companies like Jiangsu Enhua[22]. - The ongoing healthcare reforms and policies, such as centralized procurement, are pushing pharmaceutical companies to innovate and improve their R&D capabilities[21]. Research and Development - The company has a robust product pipeline with 22 innovative drug projects and 38 generic drug projects currently under development, alongside 15 projects undergoing consistency evaluation[23]. - The company increased R&D investment to CNY 495,383,504.42, a growth of 23.10% compared to the previous year, with over 70 ongoing research projects[30]. - There are currently 22 innovative drug projects under development, including 1 in Phase II clinical trials and 4 in Phase I clinical trials, with 5 projects expected to submit clinical applications in 2023[30]. - The company has launched 38 generic drug projects, with 2 generic drug production approvals obtained during the reporting period[30]. - The company has applied for 127 invention patents and received 44 authorized invention patents during the reporting period[30]. Corporate Governance - The company reported a commitment to improving corporate governance, aligning with regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange, enhancing internal control systems[97]. - The board of directors consists of four independent directors, exceeding one-third of the total board members, ensuring compliance with governance standards[98]. - The company has established a mechanism to prevent major shareholders from occupying company funds, safeguarding the interests of minority shareholders[97]. - The company emphasizes transparent communication with investors, implementing various channels for interaction, including online platforms and direct communication[99]. - The company has a comprehensive human resources management system that includes detailed regulations on recruitment, training, compensation, and performance evaluation[154]. Environmental Responsibility - The company strictly adheres to environmental protection laws and regulations, ensuring wastewater and air emissions meet national standards[143]. - The company invested approximately CNY 15.22 million in environmental governance and protection, including the purchase of environmental protection equipment and facility upgrades[151]. - The company implemented a wastewater treatment system with a capacity of 800 tons per day at the Jinshanqiao plant, ensuring that treated wastewater meets discharge standards[146]. - The company achieved over 95% efficiency in VOC treatment after upgrading its exhaust gas treatment systems, with an investment of CNY 3 million in 2022[147]. - The company has not faced any administrative penalties related to environmental issues in 2022[152]. Social Responsibility - The company actively participates in charitable activities, contributing medicines and funds to local poverty alleviation efforts, enhancing its social responsibility image[99]. - The company has established the "Enhua Caring Fund," which has donated a total of 807,800 yuan to assist socially disadvantaged families over the past seven years[159]. - The company collaborates with Nanjing Medical University to provide 60,000 yuan in scholarships annually to outstanding students in the field of psychiatry[159]. - The company has committed 480,000 yuan to support rural revitalization efforts, directly benefiting local communities[160]. - The company has been fulfilling its social responsibilities by supporting education, culture, science, and health initiatives in local areas[159]. Future Outlook - The company aims for approximately 15% growth in business revenue, total profit, and net profit in 2023 compared to the audited data of 2022[86]. - The company plans to advance 6 innovative drug clinical trials in 2023 and aims to establish 3-5 new innovative drug projects, with a goal of submitting 5 innovative drug applications for clinical trials[86]. - The company is focusing on high-barrier generic drugs and has 4 projects undergoing consistency evaluation, with 3 expected to be approved in 2023[87]. - The company is enhancing its marketing strategies to strengthen new product market access and aims to maintain its leading position in the central nervous system drug sector[88]. - The company is committed to optimizing production management and cost control, with a focus on improving product quality and reducing complaints[87].

江苏恩华药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002262 证券简称：恩华药业 公告编号：2023-012 江苏恩华药业股份有限公司（以下简称"公司"）定于2023年3月28日（星期二）15:00- 17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 公司出席本次说明会的人员有：公司总经理孙家权、董事会秘书段保州、财务负责人李 岗生、独立董事陈国祥。 问题征集专题页面二维码 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前向投资者公 开征集问题，广泛听取投资者的意见和建议。投资者可于2023年3月27日（星期一）17：00前 访问https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。公司将在2022年度业 绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会 ...

Group 1: Company Overview and Investor Relations - Jiangsu Enhua Pharmaceutical Co., Ltd. is actively engaging with investors through various activities, including specific object research and analyst meetings [1] - The company has established a mobile medical subsidiary, demonstrating its commitment to the long-term direction of internet healthcare [2] Group 2: Product Development and Market Strategy - The approval process for the new drug Etacapone is progressing, and its approval is deemed significant for the company [2] - The company primarily conducts its own research and development, with minimal outsourcing [2] - The market potential for the drug Remifentanil is substantial, leading to a collaborative approach with Renfu to expand market share [3] Group 3: Financial Performance and Growth Projections - Recent years have seen a decline in revenue growth due to factors such as medical insurance cost control and product price reductions [3] - The company anticipates that the completion of drug bidding processes in various provinces will positively impact revenue growth in the upcoming quarters [3] - Key products like Duloxetine, Aripiprazole, and Remifentanil are expected to contribute to revenue growth as they are gradually introduced into the market [4] Group 4: Employee Stock Ownership Plan - The first phase of the employee stock ownership plan was completed on August 28, 2015, with a total of 2,218,693 shares held, representing approximately 0.46% of the company's total equity [4] - The plan does not guarantee minimum returns or set performance assessment targets, relying instead on the company's sustained performance for potential returns [4] Group 5: Consistency Evaluation of Drugs - The company is actively working on drug consistency evaluations, aiming for its main products to pass the first batch of evaluations [5]

Group 1: Company Strategy and Competitive Advantage - The company will focus on increasing R&D investment and attracting high-level talent to address competition in the CNS field [2] - The strategic focus remains on the CNS area, with an emphasis on product innovation and marketing model innovation [2] - The company plans to gradually enter the biopharmaceutical field starting with genetic testing due to challenges in the mental and neurological areas [2] Group 2: Product Development and Pipeline - There are approximately 10 products with over 100 million in revenue, with 3-4 expected to exceed 500 million [3] - Short-term products will focus on completing consistency evaluations, while mid-term products include several under development [3] - Long-term innovation products include various formulations and derivatives, with rapid progress in consistency evaluations for several key products [3] Group 3: Mergers and Acquisitions - The company is considering potential acquisition targets that align with its strategic goals and product synergies [4] - Acquisitions will focus on products that complement existing offerings rather than simply increasing profits [4] Group 4: Sales and Marketing Strategy - The sales team currently consists of around 1,300 members, expected to grow to 1,500 [6] - The company has implemented a sales line reform to enhance efficiency and motivation among sales personnel [5] - Strategies to address competition include focusing on product specialization and attracting high-end R&D and sales talent [6] Group 5: Financial Performance and Projections - The company anticipates a compound annual growth rate (CAGR) of over 20.5% in the next three years, potentially reaching 27-28% without equity incentive costs [7] - The company aims to strengthen its core competencies before pursuing larger-scale growth [7] Group 6: Non-operating Income and Incentives - Non-operating income primarily stems from government compensation related to relocation, with future amounts not exceeding 4 million annually [5] - The equity incentive program focuses on R&D and marketing personnel, with clear assessment criteria established [6]